Skip to content

Clinic-Based Atopic Dermatitis Therapeutic Patient Education

A Randomized Controlled Study of Clinic-Based Atopic Dermatitis Therapeutic Patient Education

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04352270
Acronym
AD-TPE
Enrollment
56
Registered
2020-04-20
Start date
2023-02-27
Completion date
2023-09-21
Last updated
2024-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Keywords

Therapeutic patient education, Printed handouts, Educational videos, Child-parent dyads

Brief summary

The primary objective of this randomized trial is to determine whether comprehensive, accessible, and animation-style videos are a more effective method of therapeutic patient education (TPE) based on clinical outcomes than paper handouts in Spanish and English-speaking communities. The clinical outcomes being measured are the severity, sleep affected by atopic dermatitis (AD), and the amount of itch experienced.

Detailed description

Patients will be recruited, stratified, and then randomly assigned into one of two intervention groups.The patient participants will be children anywhere on the spectrum of mild to severe AD and they will be stratified into four strata: a) Those with severe AD and no medical intervention escalation, b) Those with mild AD and no medical intervention escalation, c) Those with severe AD and medical intervention escalation, and d) Those with mild AD and medical intervention escalation. Group 1 will be a paper handout for group 1 and an educational video for group 2 as a form of TPE. Subjects will be recruited in clinic after they are screened for AD during their regular dermatology appointment. The research team will provide the patient and parent with a brief introduction to the study, what it involves for the patient, any foreseeable risks, and the compensation. If they agree to participate, a consent/permission form will be given to the parent/guardian to sign. After an initial evaluation of the patient's AD, subjects will receive an initial survey and POEM questionnaire on an iPad via RedCap that will address the condition of their AD. The patient will be administered a form of TPE as the intervention. The intervention will first be viewed/read in clinic, followed by a brief set of questions from the research team to determine the amount of information retained on an immediate level. A follow-up appointment will be scheduled for the patient. Group 2 will receive a slip of paper with a link to the videos, so the TPE will be accessible outside the clinic.

Interventions

OTHERAD printed educational materials

Printed educational materials in Spanish and English about coping with Atopic Dermatitis, specifically geared towards children and parents will be given to participants.

OTHERAD educational videos

Short, educational videos in English and Spanish about coping with Atopic Dermatitis, specifically geared towards children and parents will be developed. There will be Spanish and English versions of the videos, minimal text, comprehensive language, animations, and it will be administered via user friendly platforms or websites.

Sponsors

Boston University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
No minimum to 17 Years
Healthy volunteers
No

Inclusion criteria

* Boston Medical Center (BMC) patients under the age of 18 diagnosed with AD and their parents/legal guardian * Spanish or English speakers * Have access to the internet

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
Change in eczema severity based on the Patient Oriented Eczema Measure (POEM)baseline, up to 2 monthsThe Patient Oriented Eczema Measure (POEM) is a validated 7 item instrument with response categories from 0 to 4 where No days = 0, 1-2 days = 1, 3-4 days = 2, 5-6 days = 3, Every day = 4. Scoring for the POEM ranges form 0 to 28 and is interpreted by 0 to 2 = Clear or almost clear, 3 to 7 = Mild eczema, 8 to 16 = Moderate eczema, 17 to 24 = Severe eczema, 25 to 28 = Very severe eczema.
Change in eczema severity based on the Eczema Area and Severity Index (EASI)baseline, up to 2 monthsThe Eczema Area and Severity Index (EASI) is an investigator-assessed instrument measuring the severity of clinical signs in atopic dermatitis (AD). The suggested severity strata for the EASI are: 0 = clear; 0·1-1·0 = almost clear; 1·1-7·0 = mild; 7·1-21·0 = moderate; 21·1-50·0 = severe; 50·1-72·0 = very severe
Change in the severity of itchbaseline, up to 2 monthsAn investigator developed survey completed by participants with questions about itch will be used to collect data to assess this outcome.
Change in sleep qualitybaseline, up to 2 monthsAn investigator developed survey completed by participants with questions about sleep quality will be used to collect data to assess this outcome.

Secondary

MeasureTime frameDescription
Change in the overall quality of lifebaseline, up to 2 monthsAn investigator developed survey completed by participants with questions about quality of life will be used to collect data to assess this outcome.
Atopic Dermatitis related costs6 monthsBilling records will be analyzed to assess AD related costs.
Change in patient/parent confidencebaseline, up to 2 monthsAn investigator developed survey completed by participants with questions about confidence will be used to collect data to assess this outcome.
Change in knowledge of coping with Atopic Dermatitis (AD)baseline, up to 2 monthsAn investigator developed survey completed by participants with questions about their knowledge of coping with AD will be used to collect data to assess this outcome.
Satisfaction with therapeutic patient education (TPE)up to 2 monthsAn investigator developed survey completed by participants with questions about their satisfaction about TPE will be used to collect data to assess this outcome.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026